Lin Xiao

Title: Lin Xiao - Innovator in Therapeutic Agents

Introduction

Lin Xiao is a prominent inventor based in Zhejiang, China. He has made significant contributions to the field of therapeutic agents, particularly in the development of innovative treatments involving nucleic acids and CAR-modified immune cells. His work aims to enhance the efficacy of cancer therapies.

Latest Patents

Lin Xiao holds a patent for "Therapeutic agents comprising nucleic acids and CAR-modified immune cells, and uses thereof." This patent describes a therapeutic agent that includes a nucleic acid designed to be introduced into tumor or cancer cells. The agent comprises two compositions: the first includes a nucleic acid with a coding sequence for a labeling polypeptide, which modifies the surface of the tumor or cancer cell. The second composition consists of chimeric antigen receptor modified immune cells that specifically recognize and bind to the extracellular antigen determining region. This innovative therapeutic agent achieves a synergistic therapeutic effect, showcasing Lin Xiao's commitment to advancing cancer treatment.

Career Highlights

Lin Xiao is associated with Hangzhou Converd Co., Ltd., where he continues to push the boundaries of medical research and innovation. His work has garnered attention for its potential to revolutionize cancer therapies and improve patient outcomes.

Collaborations

Lin collaborates with notable colleagues, including Fang Hu and Can Chen, who contribute to his research endeavors. Their combined expertise enhances the development of groundbreaking therapeutic solutions.

Conclusion

Lin Xiao's innovative work in therapeutic agents exemplifies the potential of modern medicine to address complex health challenges. His contributions to the field of cancer treatment are paving the way for future advancements.